We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+14.9%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$272M
AUM Growth
+$12.6M
Cap. Flow
-$13.6M
Cap. Flow %
-4.98%
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$4.13M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$2.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.07M
4
CLF icon
Cleveland-Cliffs
CLF
+$1.9M
5
FERG icon
Ferguson
FERG
+$1.82M

Top Sells

Rank Stock Value
1
ACI icon
Albertsons Companies
ACI
+$4.15M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3.03M
3
GEV icon
GE Vernova
GEV
+$2.41M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.1M
5
BHC icon
Bausch Health
BHC
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 37.62%
2 Technology 22.09%
3 Industrials 8.52%
4 Financials 6.08%
5 Consumer Discretionary 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
101
Axsome Therapeutics
AXSM
$11.4B
$1.14M 0.42%
10,909
-10,594
-49% -$1.12M
FOUR icon
102
Shift4
FOUR
$3.41B
$1.12M 0.41%
+11,300
New +$985K
SRRK icon
103
Scholar Rock
SRRK
$6.32B
$1.11M 0.41%
31,230
– –
LKQ icon
104
LKQ Corp
LKQ
$6.22B
$1.09M 0.4%
29,500
-7,200
-20% -$287K
PCVX icon
105
Vaxcyte
PCVX
$8.67B
$1.09M 0.4%
33,457
+355
+1% +$11.6K
SLNO
106
DELISTED
Soleno Therapeutics
SLNO
$1.08M 0.4%
12,941
-1,403
-10% -$105K
HDB icon
107
HDFC Bank
HDB
$120B
$1.02M 0.37%
26,482
-10,000
-27% -$362K
HUBS icon
108
HubSpot
HUBS
$10.8B
$1M 0.37%
1,800
– –
MLTX icon
109
MoonLake Immunotherapeutics
MLTX
$1.47B
$989K 0.36%
20,953
-22,588
-52% -$920K
IBN icon
110
ICICI Bank
IBN
$108B
$977K 0.36%
29,047
-9,700
-25% -$321K
VERA icon
111
Vera Therapeutics
VERA
$2.27B
$954K 0.35%
40,473
-11,724
-22% -$264K
ALV icon
112
Autoliv
ALV
$8.92B
$951K 0.35%
+8,500
New +$832K
EWTX icon
113
Edgewise Therapeutics
EWTX
$4.84B
$914K 0.34%
69,723
-21,484
-24% -$310K
OCUL icon
114
Ocular Therapeutix
OCUL
$2.03B
$825K 0.3%
88,876
+3,635
+4% +$28.5K
KROS icon
115
Keros Therapeutics
KROS
$212M
$702K 0.26%
52,618
+511
+1% +$6.9K
MDGL icon
116
Madrigal Pharmaceuticals
MDGL
$11.9B
$698K 0.26%
2,305
+94
+4% +$28K
ROIV icon
117
Roivant Sciences
ROIV
$25.8B
$690K 0.25%
61,268
-54,058
-47% -$586K
NTRA icon
118
Natera
NTRA
$45.9B
$678K 0.25%
4,014
+164
+4% +$25.6K
GHRS icon
119
GH Research
GHRS
$2.03B
$637K 0.23%
+52,247
New +$573K
JD icon
120
JD.com
JD
$45.2B
$626K 0.23%
19,183
+8,000
+72% +$273K
BZ icon
121
Kanzhun
BZ
$7.8B
$560K 0.21%
31,400
+19,500
+164% +$327K
CNTA
122
DELISTED
Centessa Pharmaceuticals
CNTA
$535K 0.2%
40,684
+1,664
+4% +$21.1K
EOLS icon
123
Evolus
EOLS
$500M
$535K 0.2%
+58,042
New +$594K
CRBP icon
124
Corbus Pharmaceuticals
CRBP
$183M
$520K 0.19%
75,292
– –
RLAY icon
125
Relay Therapeutics
RLAY
$4.37B
$518K 0.19%
+149,701
New +$445K
3 4
5
6 7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2025 Portfolio in Review

As of Q2 2025, HighVista Strategies held 177 positions worth $272M, up 4.9% from $260M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $13.6M in Q2 2025, closing 31 positions and reducing 55 holdings. Its most notable exit was Albertsons Companies, an estimated $4.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Mineralys Therapeutics worth $2.03M.

  • HighVista Strategies's largest Q2 2025 buy was Mineralys Therapeutics: 150,138 shares worth $2.03M.
  • HighVista Strategies added most to Viridian Therapeutics in Q2 2025, an estimated $4.13M increase.
  • HighVista Strategies's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $2.41M.
  • HighVista Strategies fully exited Albertsons Companies in Q2 2025, selling an estimated $4.15M.
  • HighVista Strategies's ten largest holdings make up 27% of its $272M portfolio in Q2 2025.
  • HighVista Strategies opened 29 new positions and closed 31 in Q2 2025.
  • HighVista Strategies's portfolio value rose 4.9% quarter-over-quarter to $272M.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.